Observational studyMicrobiology spectrum2026
Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to vancomycin and other beta-lactam agents: a large multicenter retrospective cohort study from China.
Observational study in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Acute kidney injury (AKI) associated with vancomycin (VAN) plus piperacillin-tazobactam (PTZ) remains controversial, with over two-thirds of current evidence originating from US populations. This study evaluated AKI risk with VAN/PTZ vs VAN plus other beta-lactams (BLs) in Chinese patients, where VAN plus meropenem dominates empirical therapy. This study included patients receiving >48 h of VAN combined with a single BL. We compared AKI risk between VAN/PTZ and VAN/other-BLs. The primary outcome was incidence of stages 2-3 AKI, and the secondary outcome was major adverse kidney events at 60 days (MAKE IMPORTANCE: Acute kidney injury (AKI) associated with vancomycin (VAN) plus piperacillin-tazobactam (PTZ) remains controversial. Research evaluating this risk remains limited in Chinese cohorts. To the best of our knowledge, this multicenter retrospective cohort study is the largest study to date comparing the risk of AKI for VAN/PTZ against VAN plus other beta-lactams (BLs), VAN/meropenem (MEN), or VAN/cefepime (FEP) in the Chinese population. The study indicated that VAN/PTZ did not demonstrate an increased risk of stages 2-3 AKI and MAKE60 compared to VAN plus other BLs, as well as VAN/MEN, VAN/FEP. Our findings challenge common concerns about nephrotoxicity of VAN/PTZ mainly from Western populations and provide new safety evidence for clinical practice in China. While residual confounding inherent to observational designs remains a limitation, this study offers the highest-quality real-world evidence to date supporting non-inferior renal safety of VAN/PTZ relative to VAN plus other BLs in Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.